Revalia Bio aims to revolutionize the process of biomedical innovation by enabling catalytic failure in real world, human models of disease. 

These models derive from deceased donor human organs that are deemed unsuitable for clinical transplantation but still have massive potential to provide new insights in to human disease and response to therapy. Revalia's team leverages normothermic machine perfusion as 'mechanical patients' to bring the donor organs back to life ex vivo where they then study them for as long as 5 days. The perfused organ models can be leveraged from everything from discovery to lead optimization to generating patient stratification criteria for clincial trial design. Revalia's core expertise and technology is a full stack technology platform (including custom software, hardware and analytics) designed to maximize the knowledge extracted from every perfused organ toward massively accelerating the pace and de-risking the process of enabling breakthrough biomedical innovations to transform the lives of patients in need.